Drug Report History #179373
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v13-FR | Version v1-EN | |
|---|---|---|
| Language (Changed) | Updated to: French | Was: English |
| Date Updated (Changed) | Updated to: 2023-03-27 | Was: 2022-12-23 |
| Drug Identification Number | 00873993 | 00873993 |
| Brand name | DDAVP INJ 4MCG/ML | DDAVP INJ 4MCG/ML |
| Common or Proper name | Desmopressin Acetate | Desmopressin Acetate |
| Company Name | FERRING INC | FERRING INC |
| Ingredients | DESMOPRESSIN ACETATE | DESMOPRESSIN ACETATE |
| Strength(s) | 4MCG | 4MCG |
| Dosage form(s) | LIQUID | LIQUID |
| Route of administration | SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR | SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR SUBCUTANEOUS INTRAVENOUS INTRAMUSCULAR |
| Packaging size | 10 x 10 ml apms | 10 x 10 ml apms |
| Additional packaging sizes | ||
| ATC code | H01BA | H01BA |
| ATC description | POSTERIOR PITUITARY LOBE HORMONES | POSTERIOR PITUITARY LOBE HORMONES |
| Reason for shortage (Changed) | Updated to: Other (Please describe in comments) | Was: Demand increase for the drug. |
| Anticipated start date (Changed) | Updated to: 2022-01-20 | Was: 2022-12-23 |
| Actual start date (Changed) | Updated to: 2022-01-20 | Was: 2022-12-23 |
| Estimated end date (Changed) | Updated to: 2023-05-08 | Was: 2023-01-04 |
| Actual end date | ||
| Shortage status (Changed) | Updated to: Actual shortage | Was: Anticipated shortage |
| Tier 3 Status | No | No |
| Company comments (Changed) | Updated to: Product is on allocation | Was: |
| Health Canada comments |